Progress in unlocking the brain's "code" for depression

Clinical depression is a common psychiatric condition with often devastating consequences. A new study 新しいタブ／ウィンドウで開く in Biological Psychiatry 新しいタブ／ウィンドウで開く, published by Elsevier, advances our fundamental understanding of the neural circuitry of depression in the human brain.

Treatment of depression is complicated by the disease’s high heterogeneity and notable complexity. Medication to treat depression is available, but one third of patients do not respond to these first-line drug treatments. Other treatments such as deep brain stimulation (DBS) can provide patients with substantial relief, but previous results have been inconsistent. The development of more personalized treatments and improved outcomes requires a better understanding of the neurophysiological mechanisms of depression.

Led by Sameer Sheth, MD, PhD, at Baylor College of Medicine, together with Wayne Goodman, MD, and Nader Pouratian, MD, PhD, the researchers collected electrophysiological recordings from prefrontal cortical regions in three human subjects, all of whom experienced severe treatment-resistant depression.

The prefrontal cortex plays a significant role in psychiatric and cognitive disorders, influencing one’s ability to set goals and form habits. These highly evolved brain regions are particularly difficult to study in non-human models, so data collected from human brain activity are particularly valuable.

The researchers made electrophysiological recordings of neural activity from the surface of the brain using implanted intracranial electrodes, and they measured each participant’s depression severity for nine days. The patients were undergoing brain surgery as part of a feasibility study for treatment with DBS.

The researchers found that lower depression severity correlated with decreased low-frequency neural activity and increased high-frequency activity. They also found that changes in the anterior cingulate cortex (ACC) served as the best predictive area of depression severity. Beyond the ACC, and in alignment with the diverse nature of the pathways and symptoms of depression, they also identified individual-specific sets of features that successfully predicted severity.

“In order to use neuromodulation techniques to treat complex psychiatric or neurological disorders, we ideally need to understand their underlying neurophysiology,” Dr. Sheth said. “We are thrilled to have made initial progress in understanding how mood is encoded in human prefrontal circuits. As more such data become available, we will hopefully be able to identify which patterns are common across individuals and which are specific. This information will be critical in designing and personalizing next-generation therapies for depression such as DBS.”

John Krystal, MD, Editor of Biological Psychiatry, said of the work, "We now have a growing collection of approaches that can be applied to mapping the circuits and characterizing the neural codes underlying depression. This knowledge will guide next-generation brain stimulation treatments and inform the way we understand and treat depression, broadly."

---

Notes for editors

The article is “Decoding Depression Severity from Intracranial Neural Activity," by Jiayang Xiao, Nicole R. Provenza, Joseph Asfouri, John Myers, Raissa K. Mathura, Brian Metzger, Joshua A. Adkinson, Anusha B. Allawala, Victoria Pirtle, Denise Oswalt, Ben Shofty, Meghan E. Robinson, Sanjay J. Mathew, Wayne K. Goodman, Nader Pouratian, Paul R. Schrater, Ankit B. Patel, Andreas S. Tolias, Kelly R. Bijanki, Xaq Pitkow, and Sameer A. Sheth (https://doi.org/10.1016/j.biopsych.2023.01.020 新しいタブ／ウィンドウで開く). It appears as an Article in Press in Biological Psychiatry 新しいタブ／ウィンドウで開く, published by Elsevier.

The article is openly available at https://www.biologicalpsychiatryjournal.com/article/S0006-3223(23)00048-3/fulltext 新しいタブ／ウィンドウで開く.

Copies of this paper are also available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 254 522 9700 or [email protected] 新しいタブ／ウィンドウで開く. Journalists wishing to interview the authors may contact Sameer Sheth, MD, PhD, at [email protected] 新しいタブ／ウィンドウで開く.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here 新しいタブ／ウィンドウで開く.

About Biological Psychiatry

Biological Psychiatry 新しいタブ／ウィンドウで開く is the official journal of the Society of Biological Psychiatry 新しいタブ／ウィンドウで開く, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 12^th out of 155 Psychiatry titles and 14^th out of 274 Neurosciences titles in the Journal Citations Reports^TM published by Clarivate Analytics. The 2021 Impact Factor score for Biological Psychiatry is 12.810. 

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。